Andere Sprachen Immunocore Holdings plc

Aktien

A2QNWU

US45258D1054

IMCR

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 07.06.2024			% 5 Tage	% 1. Jan.
41,68 ^USD	-2,37 %		-14,90 %	-38,99 %

01.06.	Immunocore Holdings plc präsentiert klinische Daten zu KIMMTRAK, die zeigen, dass Patienten mit stabilem Krankheitsverlauf und bestätigter Tumorverkleinerung ähnliche klinische Ergebnisse haben wie Patienten mit teilweisem Ansprechen	CI
01.06.	Transcript : Immunocore Holdings plc - Special Call

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response	01.06.
Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response	01.06.
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response	01.06.
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024	31.05.
Immunocore Holdings plc Reports Updated Phase 1 Data of Brenetafusp (IMC-F106C), an ImmTAC Bispecific Targeting PRAME, in Immune Checkpoint Pre-treated Cutaneous Melanoma Patients at ASCO 2024	31.05.
Immunocore to present at the Jefferies Global Healthcare Conference	30.05.
Immunocore Converts Skin Cancer Therapy Phase 2/3 Trial to Phase 3	29.05.
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma	29.05.
Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma	29.05.
Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director	28.05.
Immunocore Holdings' Shares Fall After Q1 Net Loss Widens	08.05.
Earnings Flash (IMCR) IMMUNOCORE HOLDINGS Reports Q1 Revenue $70.5M	08.05.
Immunocore Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Immunocore reports first quarter financial results and provides a business update	08.05.
Avacta Group plc - Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group	01.05.
Immunocore announces upcoming presentation and posters at ASCO 2024	24.04.
Immunocore to present at upcoming investor conferences	04.04.
Immunocore Holdings Files Mixed-Securities Shelf Registration	21.03.
Immunocore presented two posters at CROI 2024	05.03.
Immunocore to present at upcoming investor conferences	01.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Immunocore Holdings plc

Aktien

A2QNWU

US45258D1054

IMCR

Andere Sprachen

Filter